Abstract
The direct-to-consumer genetic testing (DTC-GT) market has been developing for about twenty years now, raising various debates, even controversies. But what about the regulation of these so-called "innovative" devices, but whose medical status is ambiguous? A first regulatory aspect is depending on the market itself, since the latter is currently subjected to a strong structuring process. A second regulatory aspect, more classical, is the legal one. While the DTC-GT status has long been unclear on European scale, a new text (a Regulation, not a Directive) is modifying the situation. It encourages regulation "by the market" rather than "by the medical profession", which does not imply that the latter will have no (indirect) impact on the DTC-GT market.
References
Nov 29, 2008·Médecine sciences : M/S·Bertrand Jordan
Oct 9, 2009·Nature·Pauline C NgJ Craig Venter
Aug 5, 2010·Journal of the National Cancer Institute·John F Scoggins, Scott D Ramsey
Feb 9, 2011·Médecine sciences : M/S·Pascal DucournauAnne Cambon-Thomsen
Feb 9, 2011·Médecine sciences : M/S·Bertrand Jordan
Mar 3, 2011·Human Reproduction·Pascal BorryHeidi C Howard
Apr 9, 2011·Journal of Community Genetics·Pascal BorryHeidi C Howard
Nov 24, 2011·Journal of Community Genetics·Heidi Carmen Howard, Pascal Borry
Dec 30, 2011·Genome Medicine·Melanie F Myers
Jan 26, 2012·European Journal of Human Genetics : EJHG·Pascal BorryHeidi Howard
Apr 7, 2012·Médecine sciences : M/S·Bertrand Jordan
Apr 2, 2014·Médecine sciences : M/S·Bertrand Jordan
Dec 18, 2015·Médecine sciences : M/S·Bertrand Jordan
Apr 10, 2016·BMC Medical Ethics·Henri-Corto StoekléChristian Hervé
Jan 10, 2019·Médecine sciences : M/S·Henri-Corto StoekléGuillaume Vogt